Last reviewed · How we verify
WCK 4873
At a glance
| Generic name | WCK 4873 |
|---|---|
| Sponsor | Wockhardt |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase II Study of Oral Nafithromycin in CABP (PHASE2)
- Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Intravenous Nafithromycin (PHASE1)
- Evaluate The Safety, Tolerability and Pharmacokinetics Of Multiple Ascending Oral Doses Of WCK 4873 In Healthy Adult Volunteers (PHASE1)
- The Safety, Tolerability And Pharmacokinetics Of Single Ascending Doses And The Effect Of Food On Oral WCK 4873 In Healthy Adult Volunteers (PHASE1)
- A Phase 1 Pharmacokinetic Study of Single-Ascending Doses of Intravenous Nafithromycin in Healthy Adult Subjects (PHASE1)
- Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WCK 4873 CI brief — competitive landscape report
- WCK 4873 updates RSS · CI watch RSS
- Wockhardt portfolio CI